MetaVia Inc. Common Stock (MTVA)
Stock · NASDAQ · Health Care
$1.27as of 10/16/2026
Price chart
Active signals
MTVA Signal Track Record
How signals performed across all stocks →What MTVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 22 | +5.1% | 59% | October 8, 2026 |
| Bollinger Band Breakout | 20 | -23.4% | 30% | August 24, 2026 |
| Volume Spike | 18 | -18.1% | 33% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -4.3% | 29% | December 22, 2025 |
| Any 20-session window (baseline) | -7.1% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 cli…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- metaviatx.com/
Fundamentals
- 1-day range
- $1.33$1.43
- Market cap
- $7.49M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-4.05
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 81.5K
- Dividend pay date
- December 31, 2019
Forecasts
3 analyst ratings
MetaVia Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- ADXNAddex Therapeutics Ltd American Depositary Shares$2.76▼ 8.61%Market cap $7.34MP/E —$0.018$0.069
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| ADXN Addex Therapeutics Ltd American Depositary Shares | $7.34M | — | $2.76 | ▼ 8.61% | $0.018$0.069 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Michael Salsbury · June 8, 2026 · Grant17.2K
- James Patrick Tursi · June 8, 2026 · Grant17.2K
- Jason L. Groves · June 8, 2026 · Grant17.2K
- Mark A. Glickman · June 8, 2026 · Grant17.2K
- Andrew I. Koven · June 8, 2026 · Grant17.2K
- D. Gordon Strickland · June 8, 2026 · Grant17.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 60.1K
- Total value held
- $72.1K
- Institutional holders
- 11
- Unknown33.6K
- Unknown10.9K
- Unknown10.0K
- Unknown2.6K
- Unknown2.2K
- Unknown479
- Unknown205
- Unknown3
- Unknown2
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MTVA appoints Dr. Sarah Browne as Chief Medical Officer
MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.
MTVA appoints Dr. Sarah Browne as Chief Medical Officer. MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.